- Home
- WALD vs MBX Comparison
WALD vs MBX Comparison
Compare WALD & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WALD
- MBX
- Stock Information
- Founded
- WALD 1988
- MBX 36
- Country
- WALD United Kingdom
- MBX United States
- Employees
- WALD N/A
- MBX N/A
- Industry
- WALD Package Goods/Cosmetics
- MBX
- Sector
- WALD Consumer Discretionary
- MBX
- Exchange
- WALD Nasdaq
- MBX NYSE
- Market Cap
- WALD 372.2M
- MBX 347.9M
- IPO Year
- WALD 2021
- MBX 2024
- Fundamental
- Price
- WALD $3.16
- MBX $10.88
- Analyst Decision
- WALD Strong Buy
- MBX Strong Buy
- Analyst Count
- WALD 4
- MBX 4
- Target Price
- WALD $5.95
- MBX $37.25
- AVG Volume (30 Days)
- WALD 69.6K
- MBX 319.2K
- Earning Date
- WALD 03-18-2025
- MBX 03-07-2025
- Dividend Yield
- WALD N/A
- MBX N/A
- EPS Growth
- WALD N/A
- MBX N/A
- EPS
- WALD N/A
- MBX N/A
- Revenue
- WALD $240,382,000.00
- MBX N/A
- Revenue This Year
- WALD $27.29
- MBX N/A
- Revenue Next Year
- WALD $19.54
- MBX N/A
- P/E Ratio
- WALD N/A
- MBX N/A
- Revenue Growth
- WALD N/A
- MBX N/A
- 52 Week Low
- WALD $2.41
- MBX $8.63
- 52 Week High
- WALD $7.88
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- WALD 42.96
- MBX N/A
- Support Level
- WALD $3.05
- MBX N/A
- Resistance Level
- WALD $3.63
- MBX N/A
- Average True Range (ATR)
- WALD 0.17
- MBX 0.00
- MACD
- WALD -0.04
- MBX 0.00
- Stochastic Oscillator
- WALD 26.56
- MBX 0.00
About WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform by developing, acquiring, accelerating, and scaling the next generation of conscious, purpose-driven brands. It is organized into two reportable segments namely Obagi Skincare and Milk Makeup.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.